palmitoylethanolamide

AssetSmall moleculeAlso THX-110, PEA, Levagen+, Palmitoylethanolamide (PEA)

Endogenous fatty acid amide acting via PPAR-alpha and endocannabinoid-related pathways to resolve inflammation and neuropathic pain.

Stage: Phase 2
Modality: Small molecule
Target: Lipid and ceramide metabolism
Indications: 5
Trials: 10
Developers: 2

Indications

5

Anxiety
Phase 2RECRUITINGNCT07315516clinicaltrials.gov7 Oct 2026
Diabetic peripheral neuropathy
Phase 2RECRUITINGNCT07028528clinicaltrials.gov7 Oct 2026
Sleep disorders
Phase 2RECRUITINGNCT07315516clinicaltrials.gov7 Oct 2026

2 more

Targets and what it contains3
Owner and partners2
Trials10
Evidence for its targets4
Competitors7
Aging relevance1
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026 · 6 sources